Dmochowski, Roger R.
Rovner, Eric S.
Kennelly, Michael J.
Newman, Diane K.
Abedinzadeh, Laleh
Snyder, Daniel
Thomas, Elizabeth
Haag-Molkenteller, Cornelia
Rosenberg, Matt T.
Funding for this research was provided by:
Urovant Sciences
Article History
Received: 21 September 2022
Accepted: 6 April 2023
First Online: 24 April 2023
Declarations
:
: This study will be conducted in compliance with International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use/Good Clinical Practice guidelines. Investigators will receive institutional review board, research ethics board, or independent ethics committee approval before the initiation of the study. All patients will provide written informed consent.
: Not applicable.
: RRD is a consultant for Urovant Sciences. ESR has a relationship with Ion Channel Innovations, LLC; is a consultant for Urovant Sciences and Hologic; and has received research funding from Allergan, Medtronics, and Uromedica. MJK is a consultant for Allergan, Astellas, Boston Scientific, Coloplast, Laborie, and Urovant Sciences and has received grant or research study funding from Allergan, Axonics, Boston Scientific, Coloplast, Cook Myosite, Dignify Therapeutics, EBT Medical, and FemPulse. DKN is an editor at Digital Science Press; consultant for Cosm Medical, Convatec, and Urovant Sciences; and has received funding from the National Institutes of Health and the Society of Urologic Nurses and Associates. LA, ET, and DS are employees of Urovant Sciences. CH-M was an employee of Urovant Sciences at the time the study protocol was developed. MTR is a consultant and speaker for Urovant Sciences; a consultant and speaker for Astellas Pharma; and a consultant for Ferring.